Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.38 |
| ▸ | CDK9 | P50750 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2889261 | 0.86 | CCNT1 (0.42) | KDM4ENPY5RPTK2CCNT1CDK9 | |
| SCHEMBL1107408 | 0.82 | GABRP (0.44) | KDM4ENPY5RPTK2CCNT1CDK9 | |
| SCHEMBL2695837 | 0.82 | ALDH1A1 (0.43) | KDM4ENPY5RPTK2MAPTGAA | |
| SCHEMBL12304557 | 0.82 | TLR8 (0.38) | KDM4ENPY5RPTK2CCNT1CDK9 | |
| SCHEMBL18713934 | 0.81 | TSHR (0.39) | KDM4ETSHRSMN1; SMN2GAA | |
| SCHEMBL3375825 | 0.80 | TSHR (0.50) | NPY5RPTK2CCNT1CDK9TSHR | |
| SCHEMBL12171435 | 0.80 | CCNT1 (0.38) | KDM4ENPY5RPTK2CCNT1CDK9 | |
| SCHEMBL21408253 | 0.80 | TLR8 (0.37) | KDM4ENPY5RPTK2CCNT1CDK9 | |
| SCHEMBL21408260 | 0.80 | TLR8 (0.37) | KDM4ENPY5RPTK2CCNT1CDK9 | |
| SCHEMBL31418399 | 0.80 | TLR8 (0.37) | KDM4ENPY5RPTK2CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165452-A1 | Substituted Heteroaryls | PFIZER INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| WO-2010029461-A1 | HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS | PFIZER INC. (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, MPO, GCK | KDM4E 2426/4885NPY5R 1779/4885PTK2 1337/4885 |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | KDM4E 2019/4885NPY5R 1676/4885PTK2 1028/4885 |
| US-20130165452-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | KDM4E 2068/4885NPY5R 1044/4885PTK2 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.